Roche Breast Cancer Drug Fails to Win U.K. BackingBy
U.K. cost adviser says evidence of long-term benefits needed
Perjeta costs at least $10,500 depending on treatment cycles
Roche Holding AG’s Perjeta treatment for breast cancer failed to win the backing of the U.K.’s health-cost adviser, the latest salvo in an ongoing struggle between Britain and the world’s biggest maker of cancer medicines over prices.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.